Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer

Stefano Greggi, M. Giovanna Salerno, Giuseppe D'Agostino, Gabriella Ferrandina, Domenica Lorusso, Luigi Manzione, Salvatore Mancuso, Giovanni Scambia

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

24 Patients were enrolled into a phase I-II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2-7). Topotecan was administered on days 1-5 by 30 min i.v. infusion immediately after gemcitabine given by 30 min i.v. on days 1 and 3; cycles were repeated every 28 days. The starting doses were topotecan 0.7 mg/m2 and gemcitabine 200 mg/m2. Following dose levels were 08/400; 0.9/600; 0.9/800 for topotecan and gemcitabine, respectively. The maximum tolerated dose (MTD) was reached at dose level 3, the dose-limiting toxicity being represented by febrile neutropenia and thrombocytopenia. After the MTD was reached, granulocyte-colony-stimulating factor was administered in 27% of cycles. Mild and manageable was non hematological toxicity. All patients are so far evaluable for response. Among them 2 complete responses (8.3%; 95% Cl: 2.6-19), 1 partial response (4.2%; 95% Cl: 3.8-12), 9 no change (37.5%; 95% Cl: 18-56.8) and 12 progressions (50%; 95% Cl: 30-70) have been registered. Based on these data, there is no evidence that combining topotecan and gemcitabine is better than using either of the two drugs used separately.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalOncology
Volume60
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

gemcitabine
Topotecan
Paclitaxel
Platinum
Ovarian Neoplasms
Maximum Tolerated Dose
Febrile Neutropenia
Granulocyte Colony-Stimulating Factor
Thrombocytopenia

Keywords

  • Gemcitabine
  • Ovarian cancer
  • Phase I-II
  • Topotecan

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. / Greggi, Stefano; Salerno, M. Giovanna; D'Agostino, Giuseppe; Ferrandina, Gabriella; Lorusso, Domenica; Manzione, Luigi; Mancuso, Salvatore; Scambia, Giovanni.

In: Oncology, Vol. 60, No. 1, 2001, p. 19-23.

Research output: Contribution to journalArticle

Greggi, S, Salerno, MG, D'Agostino, G, Ferrandina, G, Lorusso, D, Manzione, L, Mancuso, S & Scambia, G 2001, 'Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer', Oncology, vol. 60, no. 1, pp. 19-23. https://doi.org/10.1159/000055291
Greggi, Stefano ; Salerno, M. Giovanna ; D'Agostino, Giuseppe ; Ferrandina, Gabriella ; Lorusso, Domenica ; Manzione, Luigi ; Mancuso, Salvatore ; Scambia, Giovanni. / Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. In: Oncology. 2001 ; Vol. 60, No. 1. pp. 19-23.
@article{5daaa8ed5a504b51a4d5985a8831b9f4,
title = "Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer",
abstract = "24 Patients were enrolled into a phase I-II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2-7). Topotecan was administered on days 1-5 by 30 min i.v. infusion immediately after gemcitabine given by 30 min i.v. on days 1 and 3; cycles were repeated every 28 days. The starting doses were topotecan 0.7 mg/m2 and gemcitabine 200 mg/m2. Following dose levels were 08/400; 0.9/600; 0.9/800 for topotecan and gemcitabine, respectively. The maximum tolerated dose (MTD) was reached at dose level 3, the dose-limiting toxicity being represented by febrile neutropenia and thrombocytopenia. After the MTD was reached, granulocyte-colony-stimulating factor was administered in 27{\%} of cycles. Mild and manageable was non hematological toxicity. All patients are so far evaluable for response. Among them 2 complete responses (8.3{\%}; 95{\%} Cl: 2.6-19), 1 partial response (4.2{\%}; 95{\%} Cl: 3.8-12), 9 no change (37.5{\%}; 95{\%} Cl: 18-56.8) and 12 progressions (50{\%}; 95{\%} Cl: 30-70) have been registered. Based on these data, there is no evidence that combining topotecan and gemcitabine is better than using either of the two drugs used separately.",
keywords = "Gemcitabine, Ovarian cancer, Phase I-II, Topotecan",
author = "Stefano Greggi and Salerno, {M. Giovanna} and Giuseppe D'Agostino and Gabriella Ferrandina and Domenica Lorusso and Luigi Manzione and Salvatore Mancuso and Giovanni Scambia",
year = "2001",
doi = "10.1159/000055291",
language = "English",
volume = "60",
pages = "19--23",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer

AU - Greggi, Stefano

AU - Salerno, M. Giovanna

AU - D'Agostino, Giuseppe

AU - Ferrandina, Gabriella

AU - Lorusso, Domenica

AU - Manzione, Luigi

AU - Mancuso, Salvatore

AU - Scambia, Giovanni

PY - 2001

Y1 - 2001

N2 - 24 Patients were enrolled into a phase I-II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2-7). Topotecan was administered on days 1-5 by 30 min i.v. infusion immediately after gemcitabine given by 30 min i.v. on days 1 and 3; cycles were repeated every 28 days. The starting doses were topotecan 0.7 mg/m2 and gemcitabine 200 mg/m2. Following dose levels were 08/400; 0.9/600; 0.9/800 for topotecan and gemcitabine, respectively. The maximum tolerated dose (MTD) was reached at dose level 3, the dose-limiting toxicity being represented by febrile neutropenia and thrombocytopenia. After the MTD was reached, granulocyte-colony-stimulating factor was administered in 27% of cycles. Mild and manageable was non hematological toxicity. All patients are so far evaluable for response. Among them 2 complete responses (8.3%; 95% Cl: 2.6-19), 1 partial response (4.2%; 95% Cl: 3.8-12), 9 no change (37.5%; 95% Cl: 18-56.8) and 12 progressions (50%; 95% Cl: 30-70) have been registered. Based on these data, there is no evidence that combining topotecan and gemcitabine is better than using either of the two drugs used separately.

AB - 24 Patients were enrolled into a phase I-II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2-7). Topotecan was administered on days 1-5 by 30 min i.v. infusion immediately after gemcitabine given by 30 min i.v. on days 1 and 3; cycles were repeated every 28 days. The starting doses were topotecan 0.7 mg/m2 and gemcitabine 200 mg/m2. Following dose levels were 08/400; 0.9/600; 0.9/800 for topotecan and gemcitabine, respectively. The maximum tolerated dose (MTD) was reached at dose level 3, the dose-limiting toxicity being represented by febrile neutropenia and thrombocytopenia. After the MTD was reached, granulocyte-colony-stimulating factor was administered in 27% of cycles. Mild and manageable was non hematological toxicity. All patients are so far evaluable for response. Among them 2 complete responses (8.3%; 95% Cl: 2.6-19), 1 partial response (4.2%; 95% Cl: 3.8-12), 9 no change (37.5%; 95% Cl: 18-56.8) and 12 progressions (50%; 95% Cl: 30-70) have been registered. Based on these data, there is no evidence that combining topotecan and gemcitabine is better than using either of the two drugs used separately.

KW - Gemcitabine

KW - Ovarian cancer

KW - Phase I-II

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0035165048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035165048&partnerID=8YFLogxK

U2 - 10.1159/000055291

DO - 10.1159/000055291

M3 - Article

VL - 60

SP - 19

EP - 23

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -